Overview Ropeginterferon Alfa 2b for Early Myelofibrosis Status: Recruiting Trial end date: 2025-12-31 Target enrollment: Participant gender: Summary This is a multi-centre phase 2 open-label prospective study designed to assess the efficacy and safety of ropeg patients with pre-fibrotic primary myelofibrosis or DIPSS low/intermediate-1 risk myelofibrosis after 24 months of treatment. Phase: Phase 2 Details Lead Sponsor: The University of Hong Kong